Teva begins paying down debt with $1.1B deal

The beleaguered Israeli company has $34 billion in debt and intends to sell off non-core assets to help rightsize its balance sheet.

By Lisa LaMotta • Sept. 12, 2017

Prescribed Reading: PD-1, CAR-T threatened by clinical holds

Highly innovative oncology technologies may be life-saving, but they have also raised major safety concerns.

By Lisa LaMotta • Sept. 8, 2017

Merck picks up new I/O approach

The big pharma is further growing its I/O portfolio by acquiring RIG-I targeting therapeutics startup Rigontec.

By Suzanne Elvidge • Sept. 7, 2017

Bioverativ and Bicycle keep rare disease deals rolling

Through a new research collaboration, the companies are looking for new treatments for hemophilia as well as the more common sickle cell disease.

By Jacob Bell • Sept. 6, 2017

3SBio snaps up Therapure CDMO for $290M

The Chinese company looks to the West for further expansion into drug development and manufacturing.

By Suzanne Elvidge • Sept. 5, 2017

Industry Pulse: 10 charts on M&A, I/O and biosimilar threats

While Gilead's acquisition of Kite lifted the biotech sector, major dealmaking has been few and far between this year. Elsewhere, copycat biologics pose a growing threat to industry top-sellers. 

By Ned Pagliarulo • Sept. 1, 2017

Janssen drops MacroGenics cancer candidate over safety concerns

Progress from CAR-T therapies, coupled with neurotoxicity observed in a Phase 1 study, appear to have cooled the J&J subsidiary's interest in the bispecific. 

By Ned Pagliarulo • Sept. 1, 2017

Prescribed Reading: Get ready for CAR-T clash

The biggest deal of the year and a major approval were both based around CAR-T technology, setting up the market for a price war in the space. 

By Lisa LaMotta • Sept. 1, 2017

Acorda builds its defense against potential takeover

As an activist investor pushes for a sale, the neurology-focused drugmaker hopes a new Rights Agreement will protect it from such an end.

By Jacob Bell • Sept. 1, 2017

Daiichi calls off pain collaboration with Charleston

In an effort to restructure and become an oncology powerhouse, the Japanese pharma is paring down its pipeline.

By Lisa LaMotta • Aug. 31, 2017

Five Prime ditches Inhibrx deal after two years

Five Prime has dumped its La Jolla biotech partner, Inhibrx, and terminated tetravalent antibody development.

By Suzanne Elvidge • Aug. 31, 2017

MedCo gets FDA OK on antibacterial, boosting sale potential

The approval makes the antibiotics developer's infectious disease business more valuable, a plus given that the company is looking to sell the unit.

By Lisa LaMotta • Aug. 30, 2017

CSL Behring pays $91M upfront for early stage gene therapy

Purchase of a Tucson biotech brings CSL Behring into the stem cell gene therapy arena.

By Suzanne Elvidge • Aug. 30, 2017

Celgene pays high upfront to extend deal with Forma

The big biotech handed over $195 million to keep a drug development partnership between the two companies going until October 2019.

By Jacob Bell • Aug. 29, 2017

Jazz, ImmunoGen partner on hematology, oncology drug development

The partners will investigate combination therapies for acute myeloid leukemia using Jazz's recently approved cancer med, Vyxeos.

By Jacob Bell • Aug. 29, 2017

AstraZeneca strikes $400M deal with Takeda for Parkinson's drug

Selling off or partnering on non-core assets has been a major part of the British drugmaker's strategy to manage a stretch of patent expiries for top-sellers.

By Ned Pagliarulo • Aug. 29, 2017

Daiichi Sankyo hands off cancer drug to Boston Pharma

The Japanese pharma sold off a cancer compound from its crowded portfolio to Boston Pharmaceuticals, where it may have a better chance of moving to market

By Suzanne Elvidge • Aug. 29, 2017

Kite flying high on $12B takeout by Gilead

The big biotech, long under pressure to make a deal, is using part of its cash stockpile to pick up the hot CAR-T company. 

By Lisa LaMotta • Aug. 28, 2017

Xoma clears debt with Novartis licensing deal

The big pharma will spend $31 million upfront and pay down part of Xoma's debt to gain access to the biotech's anti-inflammatory drug. 

By Suzanne Elvidge • Aug. 28, 2017

Prescribed Reading: Biosimilars or biologics? Why not both?

A few small deals, plenty of stock movement on clinical trial results and several new therapies inch closer to market. 

By Lisa LaMotta • Aug. 25, 2017

Regenxbio picks up Dimension in $86M stock deal

The all-stock acquisition will give Regenxbio access to one clinical and several preclinical gene therapy candidates.

By Ned Pagliarulo • Aug. 25, 2017

Dr. Reddy's sells off psoriasis candidate in out-licensing deal

In the midst of a challenging year, the Indian drugmaker inked a deal that could be worth up to $32.5 million in milestone payments. 

By Suzanne Elvidge • Aug. 23, 2017

Novogen irons out Phase 2 plans for brain cancer candidate

Contract research organization Chiltern will help the company conduct a mid-stage study slated for the fourth quarter.

By Jacob Bell • Aug. 22, 2017

Stada takeover inches closer

Cinven and Bain have cleared the first hurdle to a Stada takeover with more than 63% shareholder acceptance — but there's still a ways to go.

By Suzanne Elvidge • Aug. 22, 2017

AstraZeneca taps Ethris in RNA deal

The five-year deal focuses on discovery and development of respiratory treatments, adding to the big pharma's growing respiratory portfolio.

By Suzanne Elvidge • Aug. 22, 2017